SCHEMBL20161706

SCHEMBL20161706

CC(C)OC(=O)CC1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.33
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33
PRKCZ Q05513 1/20 0.33
PRKCD Q05655 1/20 0.33
PRKD1 Q15139 1/20 0.33
MIF P14174 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 2/20 0.33
SELP P16109 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9254155 0.86 LMNA (0.38) MIFCYP3A4MAPTCYP2C9CYP2C19
SCHEMBL18214224 0.83 PYGB (0.44) SELPPYGBCA9CA12CA2
SCHEMBL20161669 0.78 GAA (0.38) FUCA1PRKD3PRKCGPRKCBPRKCA
SCHEMBL11688739 0.78 LMNA (0.41) MIFCYP3A4MAPTCYP2C9CYP2C19
SCHEMBL27015534 0.77 FUCA1 (0.36) FUCA1PRKD3PRKCGPRKCBPRKCA
SCHEMBL9914017 0.76 FUCA1 (0.40) FUCA1SELPPYGBCA9CA12
SCHEMBL9915194 0.76 FUCA1 (0.40) FUCA1SELPPYGBCA9CA12
SCHEMBL14025396 0.76 FUCA1 (0.40) FUCA1SELPPYGBCA9CA12
SCHEMBL20161471 0.76 FUCA1 (0.40) FUCA1SELPPYGBCA9CA12
SCHEMBL9914020 0.76 FUCA1 (0.40) FUCA1SELPPYGBCA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same L'OREAL (FR) 2021-06-29 US disclosed
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME L'OREAL (FR) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133137-A1 PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME KRT18, CUTA, GLA FUCA1 58/4885PRKD3 631/4885PRKCG 132/4885
US-11045411-B2 Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same KRT18, CUTA, GLA FUCA1 58/4885PRKD3 631/4885PRKCG 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.